Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 13/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397221 | 0.90 | P2RY6 (0.61) | P2RY6HSD17B10FFAR1LMNAMIF | |
| SCHEMBL7603799 | 0.84 | P2RY6 (0.63) | P2RY6HSD17B10FFAR1CA1CA2 | |
| SCHEMBL7686608 | 0.84 | P2RY6 (0.63) | P2RY6HSD17B10KEAP1LMNACA1 | |
| SCHEMBL1457228 | 0.81 | P2RY6 (0.59) | P2RY6HSD17B10FFAR1LMNACA1 | |
| SCHEMBL9547715 | 0.80 | P2RY6 (1.00) | P2RY6HSD17B10CA1CA2MIF | |
| SCHEMBL1853024 | 0.80 | P2RY6 (1.00) | P2RY6HSD17B10CA1CA2MIF | |
| SCHEMBL3763772 | 0.80 | P2RY6 (0.58) | P2RY6HSD17B10LMNA | |
| SCHEMBL69746 | 0.78 | FFAR1 (0.81) | FFAR1KEAP1FFAR4LMNAL3MBTL1 | |
| SCHEMBL8503279 | 0.77 | P2RY6 (0.76) | P2RY6HSD17B10CA1CA2MIF | |
| SCHEMBL18902133 | 0.77 | FFAR1 (0.61) | FFAR1KEAP1FFAR4LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153781-B2 | Dendrimer conjugates of agonists and antagonists of the GPCR superfamily | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2170401-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPA (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009006046-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012035-A1 | DENDRIMER CONJUGATES OF AGONISTS AND ANTAGONISTS OF THE GPCR SUPERFAMILY | ADORA1, ADORA2A, ADORA3 | P2RY6 119/4885HSD17B10 4279/4885FFAR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.